I'm very surprised by the valuation that the market has applied to Biotron in this current climate.
Phase 2 trials targetting the co-infected HIV and HCV population is serious stuff.
The medical implications of such disease are enormous with serious morbidity as high as 85%.
When the re-rating comes for this stock, it will be very large.
The big question is when will the market latch on??
waiting, page-4
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
